Dynavax Highlights Comparable Efficacy and Improved Tolerability of Z-1018 Shingles Vaccine vs. Shingrix
Dynavax's experimental shingles vaccine Z-1018 achieved an 89.7% vaccine response rate in Phase 1/2 trials, closely matching Shingrix's 90.3% response rate in adults aged 50-6915.
The selected Z-1018 formulation achieved a 100% humoral antibody response versus Shingrix’s 96.9%, and robust cellular immunity comparable to Shingrix (89.7% vs. 93.5% cellular response)4.
Z-1018 showed a significantly improved safety and tolerability profile:
only 12.5% of participants reported grade 2-3 local reactions and 27.5% reported grade 2-3 systemic reactions, compared to 52.6% and 63.2% for Shingrix, respectively—a more than 50% reduction in adverse reactions1345.
Dynavax will advance Z-1018 trials to participants aged 70 and older in late 2025, with regulatory approval efforts anticipated if broader efficacy and safety are confirmed123.
Positive topline data has strengthened Dynavax's competitive position, with the company aiming to challenge Shingrix’s market dominance by providing comparable protection with fewer side effects34.
Sources:
1. https://www.ainvest.com/news/dynavax-1018-shows-89-7-efficacy-50-side-effects-shingrix-2508/
2. https://stocktwits.com/news-articles/markets/equity/dynavax-experimental-shingles-vaccines-shows-positive-results-in-study/chsj5HjRdit
3. https://www.fiercebiotech.com/biotech/dynavaxs-shingles-vaccine-holds-its-own-against-shingrix-early-clinical-test
4. https://www.stocktitan.net/news/DVAX/dynavax-announces-positive-topline-phase-1-2-results-supporting-3rhjy69sboqw.html